Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata

Role of janus kinase inhibitors in the treatment of alopecia areata

“…In terms of safety, reported side effects include only mild symptoms, grade I and II infections, as well as transient elevation of liver transaminase, and cholesterol level ( Table 1 ). 38 , 39 , 47 , 48 , 50 , 57 Most of these symptoms or abnormalities were transient and reversible either spontaneously or with discontinuation of tofacitinib. One retrospective study by Ibrahim et al reported a patient having morbilliform eruption and peripheral edema leading to cessation of oral tofacitinib.…”

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients

“…Previous research examining the epidemiology of SSSS has been limited by small sample sizes or confined to populations abroad. [1][2][3] To better characterize the epidemiology of SSSS in the United States, we generated national hospitalization estimates for SSSS using the 2010-2014 National Inpatient Samples, which are resources sponsored by the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality. 4 Alopecia areata patient 1 before (A) and after 4 months (B) and 6 months (C) of treatment with tofacitinib 2% ointment.…”

“…Although oral Janus kinase (JAK) inhibitors have emerged as promising targeted treatment for AA, 1 data regarding topical JAK inhibitors are lacking. 2,3 Here, we describe the results of a 24-week, openlabel, single-center pilot study of 10 patients with AA treated with tofacitinib 2% ointment applied twice daily. Inclusion criteria included $18 years of age, AA with $2 patches of scalp hair loss or complete scalp hair loss, stable or worsening disease for $6 months, and no treatment of AA for $1 month before study enrollment.…”

Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes

“…Although not as efficacious as oral therapy, topical formulations of JAK inhibitors, including tofacitinib and ruxolitinib ointment and cream in concentrations of 1% to 2%, may have some efficacy in the treatment of AA. 1 , 2 , 3 , 4 In this case, a solution was chosen as the vehicle for tofacitinib, as it would provide greater ease of application to the eyelid margin and perhaps improved penetration.…”